Modality
Gene Editing
MOA
CD3xCD20
Target
C5
Pathway
Amyloid
PVCSU
Development Pipeline
Preclinical
~Sep 2011
→ ~Dec 2012
Phase 1
~Mar 2013
→ ~Jun 2014
Phase 2
~Sep 2014
→ ~Dec 2015
Phase 3
~Mar 2016
→ ~Jun 2017
NDA/BLA
Sep 2017
→ Jun 2030
NDA/BLACurrent
NCT05723959
1,501 pts·PV
2017-09→2030-06·Completed
1,501 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-06-094.2y awayPh3 Readout· PV
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
NDA/BLA
Complet…
Catalysts
Ph3 Readout
2030-06-09 · 4.2y away
PV
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05723959 | NDA/BLA | PV | Completed | 1501 | Safety |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-9749 | Eli Lilly | Phase 3 | C5 | |
| RHH-1546 | Roche | Phase 2/3 | C5 | |
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| Zorizanubrutinib | Novo Nordisk | Phase 1 | BTK | |
| BAY-6035 | Bayer | Phase 1 | C5 | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| ARG-1250 | Argenx | Phase 2 | C5 | |
| ITC-1028 | Intra-Cellular | Phase 2 | BCMA | |
| Elratapinarof | Halozyme | Phase 2 | C5 |